Previous 10 | Next 10 |
Purple Biotech Ltd. (PPBT) is expected to report $-0.22 for Q3 2023
New patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that har...
2023-10-30 17:18:07 ET More on Purple Biotech Seeking Alpha’s Quant Rating on Purple Biotech Historical earnings data for Purple Biotech Financial information for Purple Biotech For further details see: Purple Biotech files to sell 4.65M ADS for ho...
REHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune ev...
2023-10-17 10:48:51 ET Purple Biotech ( PPBT ) Tuesday announced a registered direct offering of 4.35M of its American Depositary Shares (ADSs) for $1.15 per ADS. In addition, in a concurrent private placement, the company would issue unregistered warrants to purchase up to 4.35M ...
2023-10-17 10:00:06 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...
2023-10-17 08:25:48 ET Losers: Evelo Biosciences ( EVLO ) -40% announces top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis . Purple Biotech Ltd ( PPBT ) -21% announces $5 Million registered direct offering. Netscout Systems...
REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor imm...
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resis...
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab ; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial response NT219 exposure at the highest dose level reaching human equi...
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Purple Biotech Ltd ADR (Sponsored) Level 3 Website:
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its ...
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...